Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial
C Collins, J F Eary, G Donaldson, C Vernon, N E Bush, S Petersdorf, R B Livingston, E E Gordon, C R Chapman, F R Appelbaum, C Collins, J F Eary, G Donaldson, C Vernon, N E Bush, S Petersdorf, R B Livingston, E E Gordon, C R Chapman, F R Appelbaum
Abstract
Samarium-153-ethylenediaminetetramethylene phosphoric acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.
Source: PubMed